FolioLanternBeta
TEVATeva Pharmaceutical Industries Ltd

Evan Lippman

EVP, Business Development at Teva Pharmaceutical Industries Ltd, as of Aug 19, 2026Sold $2.2M of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
70%†
share of stake sold at Teva Pharmaceutical Industries Ltd
† Measured against shares held at the start plus shares received, because most of the shares sold arrived during the period.
26K
shares held after the latest filing, Teva Pharmaceutical Industries Ltd
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
1
company filed for

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMarAprMay 2026: $1.5M under a disclosed plan$1.5MMayJunJulAug 2026: $680K under a disclosed planAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Teva Pharmaceutical Industries Ltd (TEVA)EVP, Business DevelopmentMay 19, 2025Aug 19, 2026

Recent filings

The last 2 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.